0.72
0.72 (0%)
As of Feb 14, 2025
Ocugen, Inc. [OCGN]
Source:
Company Overview
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics and vaccines that improve health and offer hope for patients across the globe.
| Country | United States |
| Headquarters | malvern, pennsylvania |
| Phone Number | 484-328-4701 |
| Industry | manufacturing |
| CEO | Shankar Musunuri |
| Website | ocugen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $4.1 |
| Operating Profit | $-54.8 |
| Net Income | $-54.1 |
| Net Cash | $19.4 |
Profit Ratios
| Gross Margin | $4.1 |
| Operating Margin | -1,350.4 |
| Profit as % of Revenues | -7.5% |
| Profit as % of Assets | -73.6% |
| Profit as % of Stockholder Equity | -182.4% |
Management Effectiveness
| Return on Equity | -182.4% |
| Return on Assets | -65.6% |
| Turnover Ratio | 5.5% |
| EBITA | $-54.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $82.4 |
| Total Liabilities | $52.8 |
| Operating Cash Flow | $-42.1 |
| Investing Cash Flow | $-3.4 |
| Financing Cash Flow | $64.9 |
